AU1893492A - Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor - Google Patents

Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor

Info

Publication number
AU1893492A
AU1893492A AU18934/92A AU1893492A AU1893492A AU 1893492 A AU1893492 A AU 1893492A AU 18934/92 A AU18934/92 A AU 18934/92A AU 1893492 A AU1893492 A AU 1893492A AU 1893492 A AU1893492 A AU 1893492A
Authority
AU
Australia
Prior art keywords
comtaining
alpha
treatment
reductase inhibitor
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18934/92A
Inventor
Glenn J Gormley
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1893492A publication Critical patent/AU1893492A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
AU18934/92A 1991-04-17 1992-04-06 Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor Abandoned AU1893492A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68672091A 1991-04-17 1991-04-17
US686720 1991-04-17
US74638891A 1991-08-16 1991-08-16
US746388 1991-08-16
US84615592A 1992-03-11 1992-03-11
US846155 1992-03-11

Publications (1)

Publication Number Publication Date
AU1893492A true AU1893492A (en) 1992-11-17

Family

ID=27418473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18934/92A Abandoned AU1893492A (en) 1991-04-17 1992-04-06 Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor

Country Status (5)

Country Link
AU (1) AU1893492A (en)
IE (1) IE921239A1 (en)
IL (1) IL101574A0 (en)
PT (1) PT100388A (en)
WO (1) WO1992018132A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
EP0725074A3 (en) * 1992-04-20 1996-11-20 Sankyo Co Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
AU8559598A (en) * 1997-08-08 1999-03-01 Ono Pharmaceutical Co. Ltd. Gamma-type regulators for peroxisome proliferator-activated receptor
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
EP1253966B1 (en) * 1999-08-13 2011-04-27 Curadis GmbH Substances and agents for positively influencing collagen
NL1012886C1 (en) 1999-08-23 2001-02-26 Rephartox 1,4-Dihydropyridine-5-carboxylic acid ester derivatives and process for their preparation.
CO5271688A1 (en) * 1999-11-10 2003-04-30 Pfizer Prod Inc USE OF APOLIPROTEIN B AND / OR SECRETION INHIBITOR OF MICROSMAL TRIGLICERID TRANSFER PROTEIN
DE10054294A1 (en) * 2000-11-02 2002-05-16 Heinrich Wieland Topical treatment for mastalgia
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
MXPA05007572A (en) * 2003-01-17 2005-11-17 Threshold Pharmaceuticals Inc Treatment of benign prostatic hyperplasia.
EP1641464A4 (en) 2003-06-30 2008-05-14 Merck & Co Inc 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521292A (en) 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521293A (en) 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012035553A1 (en) * 2010-09-15 2012-03-22 Ind-Swift Laboratories Limited Process for preparing androstenone derivatives
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
WO2014078895A1 (en) * 2012-11-21 2014-05-30 The University Of Sydney Omega-3 analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
ATE269066T1 (en) * 1989-07-07 2004-07-15 Endorech Inc COMBINATION THERAPY FOR THE PROPHYLAXIS AND/OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Also Published As

Publication number Publication date
WO1992018132A1 (en) 1992-10-29
IE921239A1 (en) 1992-10-21
PT100388A (en) 1993-07-30
IL101574A0 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
AU1893492A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
SG80530A1 (en) Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen
GB2262229B (en) Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase i nhibitor
IL110455A0 (en) Pharmaceutical compositions for preventing the development of restenosis or intimal hyperplasia
EP0667769A4 (en) Use of alpha-1c specific compounds to treat benign prostatic hyperplasia.
AU6594796A (en) Photoactivatable compounds for the prevention of intimal hyperplasia and other diseases
AU1448595A (en) Prostatic drug-delivery catheter
AU3299195A (en) Inhibition of helicobacter
IL128331A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU2265895A (en) Inhibition of liver cancer by the use of gnrh and gnrh analogs
EP0646007A1 (en) NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS.
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
HUP0102646A3 (en) Phthalazine derivatives phosphodiesterase 4 inhibitors and pharmaceutical compositions containing the same
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
IT1272924B (en) PROCEDURE FOR THE PREPARATION OF CYCLOPENTADIENYL COMPOUNDS AND COMPOUNDS SO OBTAINABLE
EP0799619A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia
IL101410A0 (en) Formulation for the treatment of cancer
AU3187595A (en) Compounds for the treatment of restenosis
NO961226D0 (en) Compounds for the prevention and treatment of viral-induced tumors
HUT73678A (en) Compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
AU1450392A (en) Small peptidic compounds useful for the treatment of glaucoma
EP0589578A3 (en) Sulfonated compounds of beta-cyclodextrin polymer and inhibitory drug for vascular wall hyperplasia containing the same.
AU5270693A (en) Pharmaceutical composition for preventing or treating arteriosclerosis
AU1188492A (en) Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
AU5371694A (en) Use of the tarchonanthus camphoratus